Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exelixis (EXEL)
NASDAQ:EXEL
Exelixis (EXEL) Stock Price & Analysis
2,741 Followers
EXEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.52 - $24.34
Previous Close$22.12
Volume2.48M
Average Volume (3M)2.36M
Market Cap
$6.38B
Enterprise Value$5.64B
Total Cash (Recent Filing)$995.30M
Total Debt (Recent Filing)$189.94M
Price to Earnings (P/E)34.2
Beta0.76
Next Earnings
Jul 31, 2024EPS Estimate
$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.65
Shares Outstanding291,292,704
10 Day Avg. Volume2,491,357
30 Day Avg. Volume2,363,823
Standard Deviation0.11
R-Squared0.08
Alpha0.00240
Financial Highlights & Ratios
Price to Book (P/B)2.90
Price to Sales (P/S)13.43
Price to Cash Flow (P/CF)151.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit3.21
Enterprise Value/Ebitda19.91
Forecast
1Y Price Target
$26.60Price Target Upside21.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Exelixis News
PremiumCompany Announcements
Jacqueline Wright to Exit Exelixis Board in 2024
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityThe company's strong cash and investment position of $1.6bn provides financial flexibility and supports ongoing research and development.
Intellectual PropertyThere is potential for significant stock upside on a positive intellectual property ruling.
Pipeline DevelopmentPipeline development for cabozantinib continues with expected FDA filings, indicating potential future market expansion.
Bears Say
Earnings MissExelixis recorded diluted net income of $0.12 per share versus forecast diluted net income of $0.33 per share, underperforming mainly due to lower than expected revenue and higher than anticipated operating expenses.
Patent Litigation RiskThe ongoing patent litigation case with MSN poses a significant risk to Exelixis, with the odds currently suggesting a 70% chance of an unfavorable outcome for Exelixis.
Revenue ShortfallRevenues for cabozantinib missed consensus estimates by approximately 13%, influenced by seasonal fluctuations and increased expenses associated with Medicare Part D.
---
Ownership Overview
4.18% Insiders
28.07% Mutual Funds
30.55% Other Institutional Investors
37.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $18.52 and its highest was $24.34 in the past 12 months.
What is Exelixis’s market cap?
Currently, no data Available
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Jul 31, 2024 which is in 87 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Apr 30, 2024. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.227 by -$0.107.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is $0.31.
How many shares outstanding does Exelixis have?
Exelixis has 291,292,700 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.12 in its last earnings report, missing expectations of $0.227. Following the earnings report the stock price went down -6.564%.
Which hedge fund is a major shareholder of Exelixis?
Among the largest hedge funds holding Exelixis’s share is Farallon Capital Management, L.L.C.. It holds Exelixis’s shares valued at 639M.
---
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.60 (21.46% Upside)
$26.60 (21.46% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 94%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 771.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.00%
12-Months-Change
Fundamentals
Return on Equity
8.76%
Trailing 12-Months
Asset Growth
-10.80%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
---
EXEL Company Deck
---
EXEL Earnings Call
Q1 2024
0:00 / 0:00
---
EXEL Revenue Breakdown
89.00% Net product revenues
9.76% License revenues
1.24% Collaboration services revenues
---
EXEL Stock 12 Months Forecast
Average Price Target
$26.60
▲(21.46% Upside)
Technical Analysis
Best Analysts Covering EXEL
1 Year
1 Year Success Rate
18/21 ratings generated profit
1 Year Average Return
+103.35%
reiterated a buy rating 7 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +103.35% per trade.
---